(ZBIO) Zenas BioPharma, Common - Ratings and Ratios
Bifunctional Monoclonal Antibody, Anti-TNFa, CTLA4-Ig, Anti-IGF-1R
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 106% |
| Value at Risk 5%th | 165% |
| Relative Tail Risk | -4.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.85 |
| Alpha | 331.15 |
| CAGR/Max DD | 1.27 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.349 |
| Beta | 1.687 |
| Beta Downside | 1.142 |
| Drawdowns 3y | |
|---|---|
| Max DD | 74.96% |
| Mean DD | 40.46% |
| Median DD | 49.59% |
Description: ZBIO Zenas BioPharma, Common October 26, 2025
Zenas BioPharma, Inc. (NASDAQ:ZBIO) is a clinical-stage biopharma focused on immunology-based therapeutics. Its flagship candidate, obexelimab, is a bifunctional monoclonal antibody that simultaneously targets CD19 and FcγRIIb, positioning it for indications such as IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. The pipeline also includes ZB002 (anti-TNFα), ZB004 (CTLA-4-Ig fusion), and ZB001 (anti-IGF-1R), all aimed at leveraging novel immune-modulation mechanisms. The company, incorporated in 2019 and headquartered in Waltham, MA, rebranded from Zenas BioPharma (Cayman) Limited in August 2023.
As of the latest quarter, Zenas reported approximately $45 million in cash and marketable securities, giving it an estimated 12-month runway at its current burn rate of $3.5 million per month. The immunology market is projected to grow at a CAGR of ~9 % through 2030, driven by rising prevalence of autoimmune disorders and increasing adoption of biologics. Moreover, the company’s IND filings for obexelimab in three separate indications provide a diversified clinical risk profile, a factor that historically correlates with higher valuation multiples for early-stage biotech firms.
For a deeper quantitative assessment, you may find ValueRay’s analyst tools useful for evaluating ZBIO’s valuation and risk metrics.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-189.9m TTM) > 0 and > 6% of Revenue (6% = 900.0k TTM) |
| FCFTA -0.49 (>2.0%) and ΔFCFTA -25.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1628 % (prev 699.6%; Δ 928.6pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.49 (>3.0%) and CFO -158.5m > Net Income -189.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (42.2m) change vs 12m ago 0.91% (target <= -2.0% for YES) |
| Gross Margin -220.6% (prev -120.8%; Δ -99.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 4.14% (prev 12.39%; Δ -8.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -30.60 (EBITDA TTM -196.0m / Interest Expense TTM -6.41m) >= 6 (WARN >= 3) |
Altman Z'' -8.36
| (A) 0.76 = (Total Current Assets 296.6m - Total Current Liabilities 52.4m) / Total Assets 322.0m |
| (B) -1.63 = Retained Earnings (Balance) -524.7m / Total Assets 322.0m |
| warn (B) unusual magnitude: -1.63 — check mapping/units |
| (C) -0.54 = EBIT TTM -196.1m / Avg Total Assets 362.7m |
| (D) -4.18 = Book Value of Equity -524.8m / Total Liabilities 125.6m |
| Total Rating: -8.36 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.38
| 1. Piotroski 0.0pt |
| 2. FCF Yield -9.76% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda 0.59 |
| 6. ROIC - WACC (= -88.16)% |
| 7. RoE -73.55% |
| 8. Rev. Trend -26.31% |
| 9. EPS Trend 69.82% |
What is the price of ZBIO shares?
Over the past week, the price has changed by +29.89%, over one month by +10.67%, over three months by +123.38% and over the past year by +342.32%.
Is ZBIO a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ZBIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43.6 | 2.9% |
| Analysts Target Price | 43.6 | 2.9% |
| ValueRay Target Price | 50 | 18.2% |
ZBIO Fundamental Data Overview December 20, 2025
P/E Trailing = 2.6086
P/S = 125.5019
P/B = 9.5838
Beta = None
Revenue TTM = 15.0m USD
EBIT TTM = -196.1m USD
EBITDA TTM = -196.0m USD
Long Term Debt = 798.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 618.0k USD (from shortTermDebt, last quarter)
Debt = 798.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -114.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.62b USD (1.91b + Debt 798.0k - CCE 290.9m)
Interest Coverage Ratio = -30.60 (Ebit TTM -196.1m / Interest Expense TTM -6.41m)
FCF Yield = -9.76% (FCF TTM -158.6m / Enterprise Value 1.62b)
FCF Margin = -1057 % (FCF TTM -158.6m / Revenue TTM 15.0m)
Net Margin = -1266 % (Net Income TTM -189.9m / Revenue TTM 15.0m)
Gross Margin = -220.6% ((Revenue TTM 15.0m - Cost of Revenue TTM 48.1m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 5.04 (Enterprise Value 1.62b / Total Assets 322.0m)
Interest Expense / Debt = -803.0% (Interest Expense -6.41m / Debt 798.0k)
Taxrate = -0.0% (0.0 / -51.5m)
NOPAT = -196.1m (EBIT -196.1m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 5.66 (Total Current Assets 296.6m / Total Current Liabilities 52.4m)
Debt / Equity = 0.00 (Debt 798.0k / totalStockholderEquity, last quarter 196.4m)
Debt / EBITDA = 0.59 (negative EBITDA) (Net Debt -114.8m / EBITDA -196.0m)
Debt / FCF = 0.72 (negative FCF - burning cash) (Net Debt -114.8m / FCF TTM -158.6m)
Total Stockholder Equity = 258.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -58.97% (Net Income -189.9m / Total Assets 322.0m)
RoE = -73.55% (Net Income TTM -189.9m / Total Stockholder Equity 258.2m)
RoCE = -75.70% (EBIT -196.1m / Capital Employed (Equity 258.2m + L.T.Debt 798.0k))
RoIC = -75.93% (negative operating profit) (NOPAT -196.1m / Invested Capital 258.2m)
WACC = 12.22% (E(1.91b)/V(1.91b) * Re(12.23%) + (debt cost/tax rate unavailable))
Discount Rate = 12.23% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.89%
Fair Price DCF = unknown (Cash Flow -158.6m)
EPS Correlation: 69.82 | EPS CAGR: 50.47% | SUE: -0.17 | # QB: 0
Revenue Correlation: -26.31 | Revenue CAGR: -69.85% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.30 | Chg30d=-0.090 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-4.40 | Chg30d=+0.788 | Revisions Net=-1 | Growth EPS=+17.7% | Growth Revenue=+112.6%
Additional Sources for ZBIO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle